Skip to main content

Dr. David J. Vanderweele, M.D.

Medical Oncology (Medical Oncology Physician)

676 N Saint Clair St Ste 850
Chicago, IL 60611

Who else practices at this address →

Cook County includes primary care (3% of residents) and mental health (4% of residents) shortage areas. About shortage areas

Call (773) 111-8972

  • Medicare participating

At a glance

Years since graduation
19
In the NPI registry since
2008
Medicare patients seen, 2024
537

Licensed in Illinois since 2009, according to the Illinois Department of Financial and Professional Regulation. We show license dates only for the states that publish them in bulk; see which states do. For other states, check the state medical board.

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 2007Medical school: University of Chicago, Pritzker School of Medicine
  • 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    IL license 036123890 (first issued 2009; active)

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
537
Services billed
79,008
Patients’ average age
75
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, denosumab, 1 mg9,18043
Injection, daratumumab, 10 mg and hyaluronidase-fihj7,02022
Injection, pembrolizumab, 1 mg5,80016
Injection, fosaprepitant, 1 mg4,95023
Injection, oxaliplatin, 0.5 mg4,10211
Injection, iron sucrose, 1 mg2,40012
Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg1,87015
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg1,45918
Injection, atropine sulfate, 0.01 mg1,06017
Injection, bortezomib, 0.1 mg1,04421

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Most prescribed drugs, Medicare Part D 2024
DrugPrescriptions
Prednisone
Other prescribers in Chicago, IL
200
Orgovyx (relugolix)162
Abiraterone Acetate161
Nubeqa (darolutamide)74
Xtandi (enzalutamide)44
Cabometyx (cabozantinib s-malate)36
Gabapentin
Other prescribers in Chicago, IL
28
Tamsulosin Hcl
Other prescribers in Chicago, IL
28
Prochlorperazine Maleate
Other prescribers in Chicago, IL
16
Inlyta (axitinib)15

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 2 companies reported 14 payments worth $9,645 in total to this clinician.

By type
Consulting Fee$8,920
Food and Beverage$443
Travel and Lodging$282

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Jul 25, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 25, 2025
Consulting Fee
Xofigo · Oncology
$4,326
Jul 26, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 26, 2025
Consulting Fee
Nubeqa · Oncology
$2,524
Jun 23, 2025Pfizer Inc.
Jun 23, 2025
Consulting Fee
XTANDI · ONCOLOGY
$2,070
Jul 25, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 25, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$238
Jul 25, 2025Bayer HealthCare Pharmaceuticals Inc.
Jul 25, 2025
Travel and Lodging
Xofigo · Oncology · travel to Rosemont, IL · in-kind
$44.00

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Illinois →

Industry-funded research

Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $9,519 in research payments for these studies, mostly to the institutions running them.

  • An Open-label, Randomized, Phase III Study Comparing 177Lu-PSMA-617 in Combination With Standard of Care, Versus Standard of Care Alone, in Adult Male Patients With Metastatic Hormone Sensitive Prostate Cancer (mHSPC)
    Novartis Pharmaceuticals Corporation
  • A Phase III, Randomized, Open-Label, Multi-Center, Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment Followed by Durvalumab Alone for A…
    AstraZeneca Pharmaceuticals LP

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Chicago

Sources

NPI registry (CMS NPPES, November 2026; record last updated July 19, 2018), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1689846834. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.